{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T21:22:53Z","timestamp":1780521773006,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004599","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004599","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cllc.2025.04.012","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T13:05:51Z","timestamp":1745499951000},"page":"e382-e390.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Common Medical Comorbidities Influence Pneumonitis Risk After Chemoradiotherapy and Durvalumab Maintenance in Stage III Non\u2013small Cell Lung Cancer"],"prefix":"10.1016","volume":"26","author":[{"given":"Kim","family":"Ohaegbulam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timur","family":"Mitin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.cllc.2025.04.012_bib0001","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1002\/cncr.29056","article-title":"Analysis of stage and clinical\/prognostic factors for colon and rectal cancer from SEER registries: AJCC and collaborative stage data collection system","volume":"120","author":"Chen","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2025.04.012_bib0002","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.cllc.2025.04.012_bib0003","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1159\/000534376","article-title":"Chemoradiotherapy combined with immunotherapy in stage III non-small cell lung cancer: a systematic review and meta-analysis of efficacy and safety outcomes","volume":"102","author":"Li","year":"2024","journal-title":"Oncology"},{"key":"10.1016\/j.cllc.2025.04.012_bib0004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2020.10.008","article-title":"Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: a real-world multicentre study","volume":"142","author":"Desilets","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2025.04.012_bib0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received Durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.04.012_bib0006","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1186\/s12885-023-11520-y","article-title":"Risk factor analysis of the development of severe radiation pneumonitis in patients with non-small cell lung cancer treated with curative radiotherapy, with focus on underlying pulmonary disease","volume":"23","author":"Kim","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2025.04.012_bib0007","article-title":"Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta-regression of real-world studies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cllc.2025.04.012_bib0008","article-title":"Predictors of pneumonitis in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiation followed by consolidative Durvalumab","volume":"8","author":"Diamond","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.cllc.2025.04.012_bib0009","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cllc.2021.01.017","article-title":"Incidence and risk factors of symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation Durvalumab","volume":"22","author":"Shintani","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2025.04.012_bib0010","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.2337\/dc19-S006","article-title":"Glycemic targets: standards of medical care in diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cllc.2025.04.012_bib0011","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.puhe.2015.07.043","article-title":"Glycaemic control and associated factors among patients with diabetes at public health clinics in Johor, Malaysia","volume":"135","author":"Mahmood","year":"2016","journal-title":"Public Health"},{"key":"10.1016\/j.cllc.2025.04.012_bib0012","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ijrobp.2021.12.150","article-title":"Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage III non-small cell lung cancer: a systematic review and meta-analysis","volume":"112","author":"Wang","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2025.04.012_bib0013","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2025.04.012_bib0014","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1378\/chest.11-1193","article-title":"Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy","volume":"141","author":"Takeda","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.cllc.2025.04.012_bib0015","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3109\/0284186X.2012.718093","article-title":"A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis","volume":"51","author":"Vogelius","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.cllc.2025.04.012_bib0016","doi-asserted-by":"crossref","first-page":"e1822","DOI":"10.1002\/onco.13900","article-title":"Radiation versus Immune checkpoint inhibitor associated pneumonitis: distinct radiologic morphologies","volume":"26","author":"Chen","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.cllc.2025.04.012_bib0017","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.2217\/fon-2019-0524","article-title":"Real-world incidence and cost of pneumonitis post-chemoradiotherapy for stage III non-small-cell lung cancer","volume":"16","author":"Ryan","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.cllc.2025.04.012_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2024.101705","article-title":"Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer","volume":"15","author":"Stevens","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.cllc.2025.04.012_bib0019","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ijrobp.2023.09.050","article-title":"Pneumonitis after chemoradiotherapy and adjuvant durvalumab in stage III non-small cell lung cancer","volume":"118","author":"Edwards","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2025.04.012_bib0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1259\/bjr\/32629867","article-title":"Radiation pneumonitis in patients with lung and mediastinal tumours: a retrospective study of risk factors focused on pulmonary emphysema","volume":"85","author":"Kimura","year":"2012","journal-title":"Br J Radiol"},{"key":"10.1016\/j.cllc.2025.04.012_bib0021","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1046\/j.1365-2222.1999.00575.x","article-title":"Penicillins and cephalosporins as allergens\u2013structural aspects of recognition and cross-reactions","volume":"29","author":"Baldo","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.cllc.2025.04.012_bib0022","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4168\/aair.2015.7.5.518","article-title":"Hypersensitivity pneumonitis caused by cephalosporins with identical R1 side chains","volume":"7","author":"Lee","year":"2015","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.cllc.2025.04.012_bib0023","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.pharmthera.2007.11.001","article-title":"Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action","volume":"117","author":"Shinkai","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cllc.2025.04.012_bib0024","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","article-title":"Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases","volume":"68","author":"Zarogoulidis","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cllc.2025.04.012_bib0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.21037\/jtd.2017.12.22","article-title":"Clarithromycin mitigates radiation pneumonitis in patients with lung cancer treated with stereotactic body radiotherapy","volume":"10","author":"Takeda","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.cllc.2025.04.012_bib0026","doi-asserted-by":"crossref","first-page":"ii2","DOI":"10.1093\/jac\/dkx504","article-title":"Antibiotics in primary care in England: which antibiotics are prescribed and for which conditions?","volume":"73","author":"Dolk","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cllc.2025.04.012_bib0027","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s10875-007-9164-1","article-title":"Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation","volume":"28","author":"Alexandraki","year":"2008","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.cllc.2025.04.012_bib0028","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1189\/jlb.1207832","article-title":"Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase","volume":"84","author":"Omori","year":"2008","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.cllc.2025.04.012_bib0029","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12890-020-01376-4","article-title":"Radiation-induced lung injury: current evidence","volume":"21","author":"Arroyo-Hernandez","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.cllc.2025.04.012_bib0030","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/crj.13220","article-title":"Risk factors of radiation pneumonitis in patients with NSCLC treated with concomitant chemoradiotherapy\u2013are we underestimating diabetes?\u2013Turkish oncology group (TOG)\/lung cancer study group","volume":"14","author":"Ergen","year":"2020","journal-title":"Clin Respir J"},{"key":"10.1016\/j.cllc.2025.04.012_bib0031","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.2147\/CMAR.S210095","article-title":"Diabetes mellitus is a predictive factor for radiation pneumonitis after thoracic radiotherapy in patients with lung cancer","volume":"11","author":"Kong","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.cllc.2025.04.012_bib0032","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.281.21.2005","article-title":"Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group","volume":"281","author":"Turner","year":"1999","journal-title":"JAMA"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T20:43:27Z","timestamp":1759351407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425000828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1525730425000828"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.04.012","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Common Medical Comorbidities Influence Pneumonitis Risk After Chemoradiotherapy and Durvalumab Maintenance in Stage III Non\u2013small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}